Moreover, we then discovered that the activation of CaMKII and mTOR, which increase synaptic damage and tau phosphorylation, respectively, was significantly enhanced in the mouse models of T2DM and AD, whereas the levels of p-CREB, the downstream protein of CaMKII, were markedly down-regulated. The gene discussed is MAPT; the disease is type 2 diabetes mellitus.